Q
QuantAbundanciaAbundance, Quantified.

News

High-signal headlines only - macro events, earnings, M&A, regulatory. Listicles and analyst clickbait filtered out by default. Refreshed hourly.

24,214 signal articles · 252 in last 24h · 114,961 total before filter · latest 1h ago
252last 24h
1837last 7d
302● bullish (7d)
167● bearish (7d)
205publishers
AllMacro320Earnings886M&A102Regulatory23Product17Analyst23
✕ clear all filterssentiment: neutralSentiment:bullishneutralbearishshow all (incl. clickbait)
Twilio faces higher bar heading into quarterly earnings, says Jefferies
Proactive24d agoneutral
Twilio faces higher bar heading into quarterly earnings, says Jefferies

Twilio Inc (NYSE:TWLO) is expected to deliver second quarter results that exceed expectations on revenue and operating income, with investors likely to focus on whether the communications software company's gross profit growth can remain in the mid-teens during the second half of the year,...

📈 Earnings Snippet: Northrop Grumman
The Wall Street Journal24d agoneutral
📈 Earnings Snippet: Northrop Grumman

The defense and aerospace company said Tuesday that it expects $43.75 billion to $44.25 billion in sales in 2026, adding a quarter-billion dollars to its previous targets. Adjusted earnings are now projected at $28.

The World Cup effect leaves airlines with a tougher test
TheStreet24d agoneutral
The World Cup effect leaves airlines with a tougher test

The World Cup produced the sort of demand shock airlines crave, with international travelers booking late, accepting connections and paying unusually high fares. But that didn’t change the economics of the industry. American Airlines (AAL) added 27,000 seats on 12 routes and offered 1.45 million ...

Novo sues Lilly, claiming misleading ads in weight-loss drug battle
Reuters Videos24d agoneutralVIDEO
Novo sues Lilly, claiming misleading ads in weight-loss drug battle

<body><p>STORY: :: Novo Nordisk claims misleading ads in Eli Lilly weight-loss drug lawsuit</p><p>:: July 21, 2026</p><p>:: Maggie Fick, European Pharma Industry Correspondent</p><p>"Novo Nordisk sued rival Eli Lilly in a U.S. federal court on Tuesday, accusing the U.S. drugmaker of false advertising and claiming its weight-loss medicines outperform Novo's drugs." //</p><p>"Novo is alleging in its suit that Lilly's advertisements compare weight-loss results of about 50 pounds for its drug Zepbound with about 33 pounds for Wegovy, even though no head-to-head clinical trial has compared the highest approved doses of the medicines."</p><p>"Pharmaceutical companies regularly sue each other over claims related to patent infringement, for example, but false advertising suits, such as the one filed today, are less common."</p><p>"Novo Nordisk was first to market with its weight-loss injection Wegovy several years ago, but it later lost the lead to Eli Lilly, after that company launched a rival injection called Zepbound in the United States. Last year, Novo replaced its CEO and was forced to issue multiple profit warnings as it fell further behind Eli Lilly in this really competitive and booming obesity drug market, which analysts expect to be worth more than $100 billion by 2030. This year, Novo has actually sort of landed a counterpunch with its oral Wegovy pill. It was able to launch that drug ahead of Eli Lilly. Lilly has, in April, launched its own pill, a weight-loss pill. But Novo has managed to keep up strong sales even since the launch of Lilly's pill."</p><p>"Both companies report quarterly results in the next couple of weeks."</p><p>:: Novo Nordisk</p><p>:: Eli Lilly</p><p>The Danish company filed the lawsuit in U.S. District Court ‌in New Jersey, alleging Lilly violated federal and state false advertising and unfair competition laws, including the Lanham Act, through nationwide advertising campaigns for obesity drug Zepbound and diabetes treatment Mounjaro.</p><p>Novo alleges Lilly compared the highest approved doses of its medicines with lower doses of Novo's Wegovy and Ozempic while omitting newer, higher-dose versions that Novo says deliver greater weight loss.</p><p>But Indianapolis-based Eli Lilly said it stands firmly behind its ads, which are based on the results of its SURMOUNT-5 trial. That ⁠trial — completed in 2024 — compared patients on 10 mg or 15 mg of Lilly's Zepbound to patients on 1.7 mg or 2.4 mg doses of Wegovy. The FDA approved ​a 7.2 mg dose of Wegovy in March of this year.</p></body>

AMD just landed its biggest AI deal yet
TheStreet24d agoneutral
AMD just landed its biggest AI deal yet

AMD has broken a chip monopoly before. In the 2000s, it took server market share away from Intel’s dominant x86 processors, forcing years of price and performance competition that reshaped enterprise computing. Two decades later, AMD is attempting a similar disruption, this time against Nvidia’s ...

How to Use GE Vernova Earnings to Tell if the AI Trade Is Dead
Barrons.com24d agoneutral
How to Use GE Vernova Earnings to Tell if the AI Trade Is Dead

Demand for GE Vernova’s power generation equipment amid the AI data center building boom has sent shares to levels no one expected. Now, how the stock reacts to earnings on Wednesday can help tell investors if the AI trade is alive and well, or if more pain is coming to many stocks, beyond shares of Vernova. It’s an important report for Vernova, with shares above $1,000, up roughly 700% since the company was spun out of GE Aerospace in 2024.

Oracle stock makes rattling move after major setback
TheStreet24d agoneutral
Oracle stock makes rattling move after major setback

Oracle (ORCL) has spent two years telling Wall Street it can build AI infrastructure faster than anyone else. A land commissioner in New Mexico just made that harder. On Monday, Oracle stock fell about 3.5% to a fresh 52-week low, trading near $122 after touching $120.03 earlier in the day. ...